Camazepam

Camazepam is sold under the brands Albego, Limpidon, and Paxor.

Summary of clinical effects, Camazepam

Central nervous system (CNS) depression and coma, or paradoxical excitation, but deaths are rare when benzodiazepines are taken alone. Deep coma and other manifestations of severe CNS depression are rare. Sedation, somnolence, diplopia, dysarthria, ataxia and intellectual impairment are the most common adverse effects of benzodiazepines. Overdose in adults frequently involves co-ingestion of other CNS depressants, which act synergistically to increase toxicity. Elderly and very young children are more susceptible to the CNS depressant action. Intravenous administration of even therapeutic doses of benzodiazepines may produce apnoea and hypotension. Dependence may develop with regular use of benzodiazepines, even in therapeutic doses for short periods. If benzodiazepines are discontinued abruptly after regular use, withdrawal symptoms may develop. The amnesia produced by benzodiazepines can have medico-legal consequences.

Camazepam
Systematic (IUPAC) name
(9-chloro- 2-methyl- 3-oxo- 6-phenyl- 2,5-diazabicyclo [5.4.0]undeca- 5,8,10,12-tetraen- 4-yl) N,N-dimethylcarbamate
Identifiers
CAS number	36104-80-0
ATC code	N05BA15
PubChem	37367
DrugBank	?
Chemical data
Formula	C19H18ClN3O3
Mol. mass	371.8
Pharmacokinetic data
Bioavailability	?
Metabolism	Hepatic
Half life	?
Excretion	Renal
Therapeutic considerations
Pregnancy cat.	?
Legal status	Schedule IV(US)
Routes	Oral